Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Rebecca Sutphen, MD
Co-founder, chief medical officer, InformedDNA
Table of Contents

YOU MAY BE INTERESTED IN

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion. 
Rebecca Sutphen, MD
Co-founder, chief medical officer, InformedDNA

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login